105 results about "Glucuronide" patented technology

The present invention belongs to the field of biotechnology, and specifically relates to a GmSGT2 gene related to plant height and branch development, and a mutant thereof and the use thereof. A Glycine max mutant having fewer branches and decreased plant height is obtained by means of EMS mutagenesis, and a target gene thereof that is located by means of a map-based cloning technique is a GmSGT2 gene of Hedou 12. It is found through searching that the gene encodes soyasapogenol B glucuronide galactosyltransferase, and can galactosylate soyasapogenol B monoglucuronide, thereby affecting the plant height of Glycine max and reducing the branches of Glycine max. Therefore, the GmSGT2 mutant can be used for cultivating dwarf high-yield Glycine max varieties, and is of great significance in the breeding of ideal plant types of Glycine max and research on important agronomic traits of plants. The mutant has broad application prospects and great research value with regard to understanding the plant height and branch regulation mechanism of Glycine max and improving the process of Glycine max breeding; and can provide an excellent germplasm resource stock for regulating the close planting and high-yield breeding of Glycine max.

The specification relates to conjugates comprising a linker of Formula (IA):and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.

The invention provides a specific chromatogram construction and content determination method of the radix asparagi and radix ophiopogonis decoction preparation and a thin-layer chromatography identification method of traditional Chinese medicine flavor components in the radix asparagi and radix ophiopogonis decoction preparation. The specific chromatogram construction method of the radix asparagi decoction preparation comprises the following steps: step 1, taking mangiferin, quercetin-3-O-glucuronide, baicalin, wogonoside and ammonium glycyrrhizinate reference substances, and adding a solvent to prepare a reference substance solution; step 2, taking an Eupatorium japonicum-Liupu decoction reference sample, and adding a solvent to prepare a test solution; and 3, respectively detecting the reference substance solution and the test solution by using high performance liquid chromatography, and by taking the characteristic spectrum of the reference substance solution as a reference spectrum, selecting a common peak from the characteristic spectrum of the test solution to construct the characteristic spectrum of the radix asparagi decoction preparation.

This disclosure presents describes methods for the chemical glycosylation and glucuronidation of cannabinoids. These methods use readily available glycosyl and glucuronyl donors and offer a convenient and versatile approach to access a diverse range of cannabinoid glycosides and glucuronides. Selected compounds have been evaluated for their physicochemical properties and in vitro stability to understand the structure-property relationship and identify their potential applications. The possible uses of these compounds could span various fields, including medicine, consumer goods, and nutrition supplements.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention provides a method for extracting acacetin-7-O-glucuronide from dracocephalum moldavica, and relates to the technical field of medicine extraction. The method comprises the following steps: heating and extracting dracocephalum moldavica or dracocephalum moldavica products by adopting an alkaline solution, and precipitating the obtained extracting solution under the condition that the pH value is 1-3 to obtain a precipitate extract; mixing n-hexane, ethyl acetate, ethanol and water, and layering to obtain an upper phase solution and a lower phase solution; and dissolving the precipitate extract with a lower-phase solution, carrying out high-speed counter-current chromatography separation on the obtained sample solution, and collecting an acacetin-7-O-glucuronide fraction according to a chromatogram. According to the method, alkali extraction, acid precipitation and high-speed counter-current chromatography are combined, process conditions are optimized, the high-purity monomer of acacetin-7-O-glucuronide in dracocephalum moldavica is rapidly prepared, and the process is simple.

The invention provides a quality detection method of antiviral particles. The quality detection method adopts HPLC-MS / MS (High Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry) to simultaneously determine the following components: forsythiaside A, patchouli ketone, verbascoside, mangiferin, 5-methoxy-8-hydroxypsoralen, curcumenol, luteolin-7-glucuronide, kaempferol-3-O-rutinoside, baicalin, rutin and bergamot phenol. The detection method is a quantitative determination method for 11 active components in the antiviral particles, the detection method is short in time and low in cost, the quantitative analysis method is expected to provide reference for quality control of the antiviral particles, and the clinical curative effect and safety of the antiviral particles are guaranteed.

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating urolithiasis and preparation and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials and monomers in parts by weight: 10 to 30 parts of endothelium corneum gigeriae galli, 10 to 30 parts of rhizoma phragmitis, 10 to 30 parts of poria cocos, 10 to 20 parts of radix angelicae sinensis, 10 to 20 parts of herba cistanche, 10 to 20 parts of herba cepbalanoplosis segeti, 10 to 15 parts of fructus gardeniae, 5 to 10 parts of liquorice root and 1 to 6 parts of gossypotin 8-O-glucuronide. According to the traditional Chinese medicine theory of clearing heat, treating stranguria, dissolving stone and strengthening body resistance, modern pharmacological research is combined, scientific compatibility is carried out through chemical cutting, the synergistic effects of clearing heat, cooling blood, inducing diuresis, treating stranguria, dissolving stone, relieving pain, tonifying kidney and strengthening body resistance are achieved, the preparation process is efficient and controllable, and clinical application is safe and effective.

The invention discloses application of a pharmaceutical composition in preparation of a medicine for treating nephropathy, the nephropathy is at least one of membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and the pharmaceutical composition belongs to the technical field of pharmacy. The pharmaceutical composition is prepared from the following flavonoid components in a mass ratio: the mass ratio of the gossypothelin-8-O-beta-D-glucuronide to the hyperoside to the isoquercitrin to the myricetin to the quercetin-3 '-O-glucoside is 10 to (3.0 to 20) to (2.0 to 18) to (0.2 to 6.0) to (1 to 20). The pharmaceutical composition has obvious effects of preventing and / or treating membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and has relatively good safety.

The present invention discloses a method for constructing a fingerprint of Gualou Niu Bang decoction, relating to the technical field of analytical chemistry. The method is simple and has high precision, stability, and repeatability. Determination revealed that seven components, including geniposide, liquiritin, hesperidin, arctiin, baicalin, melaleucalyptol A-7-O-β-D-glucuronide, and wogonin, can be used as common characteristic peaks in the fingerprint of Gualou Niu Bang decoction for identification research.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a metabolic marker in preparation of a product for diagnosing abdominal aortic aneurysm. The metabolic marker comprises one or more than two of 5-delta-hydroxybutyl hydantoin, I-alpha-amino acid, PGF2 alpha, D-pyroglutamic acid, nicotine glucuronide, cysteine glutathione disulfide or Trp-P-1. Experiments prove that the metabolic marker has the advantages that the metabolic marker can be applied to the field of biomarkers, and the metabolic marker can be applied to the field of biomarkers; the seven metabolites are independently or jointly used as metabolic markers for diagnosing the abdominal aortic aneurysm and have good specificity and sensitivity.

The invention relates to the technical field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of various components in Shuanling antidiarrheal granules based on a UPLC-QQQ-MS / MS. The contents of 18 components in the Shuanling antidiarrheal granules are simultaneously determined by using an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometer. The 18 components comprise adenosine, gallic acid, protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, liquiritin, ellagic acid, kaempferitrin, narirutin, hesperidin, baicalin, oroxylin A-7-O-beta-D-glucuronide, wogonin, baicalein, wogonin, pachymic acid B and pachymic acid A. The invention further discloses a preparation method of the pharmaceutical composition. Through the UPLC-QTRAP-MS / MS combined technology, the technical prejudice that single component depends on in quality control of the traditional Chinese medicine compound preparation is broken through, the key problems that multiple components in a complex matrix are difficult to separate, low-content components are difficult to detect and the like are solved, efficient, accurate and synchronous determination of 18 components is achieved, and the method is suitable for large-scale popularization and application. A new reference path is opened up for modernized quality control of the traditional Chinese medicine compound preparation.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.

The invention discloses an intestinal tract hemostatic composition as well as a preparation method and application thereof, and relates to the field of hemostatic drugs. Wherein the catechin, the hyperoside, the isoquercitrin, the quercetin-3-O-glucuronide, the gallocatechin, the myricetin-3-O-galactoside, the proanthocyanidin B1, the proanthocyanidin B3, the syringe-3-O-glucoside and the astragalus smicus glycoside are flavonoid compounds; nuciferine, higenamine, N-methyl-higenamine and N-trans-feruloyl tyramine are taken as alkaloid compounds, and the compound is selected from the group consisting of higenamine, nuciferine, higenamine The composition has the advantages of simple preparation process, good hemostatic effect and the like, and provides a new raw material choice for the development of intestinal bleeding treatment medicines.

The invention discloses a keloid treatment gel material capable of reducing lactic acid generation, and belongs to the technical field of keloid treatment. The material is prepared by the following steps: firstly, carrying out esterification on 9-oxabicyclo [3.3. 1] nonane-2, 6-diol and S-allyl-L-cysteine to obtain an intermediate A, and then carrying out Schiff base reaction on the intermediate A and 5-methoxy heliotropin to obtain an intermediate B containing double bonds; then, copolymerizing with methylacryloylated chitosan and polyethylene glycol diacrylate under photo-initiation to form a cross-linked network structure; finally, active ingredients such as quercetin-3-O-glucuronide and luteolin-3 '-glucuronide are included, and auxiliary materials such as a humectant and a preservative are added, so that the composition is prepared. The gel has a slow release function, can effectively inhibit glycolysis, reduce lactic acid generation, scavenge free radicals and regulate inflammation and fibrosis microenvironment, has good biocompatibility and oxidation response drug release characteristics, and is suitable for prevention and treatment of keloids.

This invention discloses a recombinant glucuronide C5 epimerase mutant, expression vector, recombinant expression engineered bacteria, and their culture and induction methods, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (N29–N617) mutation (V173R–V197K–A239V–N269E) with an N-terminal maltose-binding protein (MBP) tag to a human glucuronide C5 epimerase (C5-epi). The recombinant glucuronide C5 epimerase mutant exhibits higher activity, 2.1 times that of the recombinant wild-type, and greater stability, retaining 72.5% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant glucuronide C5 epimerase is increased by 4-fold.

The invention discloses a Lactobacillus paracasei strain capable of converting licorice and enhancing the licorice to relieve lipid accumulation, oxidative damage and inflammatory response, and belongs to the technical field of microorganisms and the technical field of medicines. The lactobacillus paracasei CCFM1361 can convert glycyrrhizic acid, increase the content of glycyrrhetinic acid, glycyrrhetinic acid 3-O-glucuronide, ursolic acid and other substances, and increase the efficacy of the licorice extract, which is specifically embodied in (1) inhibiting the weight gain of high fat diet mice; (2) reducing liver lipid accumulation and lesion caused by the liver lipid accumulation; (3) the anti-oxidation level of the liver of the high-fat diet mouse is improved; (4) the inflammatory reaction caused by lipid accumulation is improved; and (4) reducing the inflammation level of the organism by activating an NF-kappa B p65 related pathway. Therefore, the lactobacillus paracasei CCFM1361 and glycyrrhizic acid have huge application prospects in production of products with the efficacy of resolving lipid accumulation and oxidative damage and inflammatory reaction caused by lipid accumulation.

The invention discloses application of C-phycocyanin and D-glucuronic acid in directly improving sperm motility in vitro and improving sperm motility after freezing recovery, and belongs to the technical field of biological medicine. According to the present invention, the mixed solution of D-glucuronic acid, C-phycocyanin, and D-phycocyanin has significant effects of in-vitro sperm motility promotion and sperm function protection, can be used for preparing the sperm motility improving drug or the sperm treatment reagent in the assisted reproduction technology, and has good application prospects.

The invention discloses an enzyme for metabolizing glyphosate as well as a gene promoter and application thereof. According to the invention, the glyphosate tolerant germplasm Kitaake is screened for the first time. Moreover, the glycosyl transferase gene GRGT1 (Os04g0206500) which plays a key role in improving the glyphosate tolerance is identified in Kitaake for the first time, and the gene expression level under the stress of glyphosate is remarkably improved due to deletion of a single base A at a site 803 in a promoter region of the glycosyl transferase gene GRGT1 (Os04g0206500). The GRGT1 protease can catalyze a glycosylation reaction between glyphosate and two glycosyl donors UDP-glucose and UDP-glucuronic acid to generate low-toxicity derivatives M331 and M345, so that the residue of glyphosate in rice is reduced. The invention systematically discloses a glyphosate-resistant glycosylation metabolism mechanism of rice, discovers a new glyphosate metabolism gene, and provides a basis for creating efficient resistant germplasm resources.

The invention relates to the technical field of medicines, in particular to application of a flavonoid metabolite for improving tacrolimus-induced chronic renal injury. The invention provides application of a flavonoid metabolite, namely quercetin-7-O-beta-glucuronide, in an abelmoschus esculentus capsule to improvement of chronic renal injury induced by tacrolimus, and particularly provides application of the flavonoid metabolite, namely quercetin-7-O-beta-glucuronide in the abelmoschus esculentus capsule. The research shows that the quincetin-7-O-beta-glucuronide has relatively strong biological activities of resisting inflammation, resisting oxidation, resisting fibrosis and the like, and plays an important role in preventing and treating the chronic renal injury caused by tacrolimus.

The invention discloses a preparation method of a pyronaphthyridine metabolite, which comprises the following steps: reacting a compound A serving as a raw material with a compound B (2, 3, 4-tri-O-acetyl-alpha-D-glucuronide methyl ester trichloroacetimidate) under the action of a catalyst to obtain a compound C, and hydrolyzing the compound C under an alkaline condition to obtain a compound D, namely the pyronaphthyridine metabolite. The preparation method disclosed by the invention is reasonable in design, simple in post-treatment, easily available in raw materials and high in operability; the purity of the prepared target product can reach 97.0% or above, the method can be used for pharmacokinetic research, a test sample is provided for research on the metabolic mechanism of the pyronaphthyridine, and the method has important application value.

The invention discloses a construction method of a trichosanthes kirilowii maxim and burdock soup fingerprint spectrum, and relates to the technical field of analytical chemistry. The determination method disclosed by the invention is simple and has the characteristics of high precision, stability and repeatability, and through determination, seven components including geniposide, liquiritin, hesperidin, arctiin, baicalin, oroxylin A-7-O-beta-D-glucuronide and wogonoside can be used as common characteristic peaks of the fingerprint spectrum of the trichosanthes kirilowii Maxim and arctium lappa decoction for identification and research.

A method for extracting flavonoid components in Dracocephalum moldavica L., comprising the following steps: mixing Dracocephalum moldavica L. and an alkaline solution for heating extraction; under the condition that the pH value is 1-3, mixing an obtained extract solution with acid for precipitation; dissolving an obtained precipitated extract and then carrying out preparative liquid chromatography separation; and respectively concentrating obtained Fr1-Fr6 fractions until the fractions are dry, so as to sequentially obtain luteolin-7-O-β-D-glucuronide, apigenin-7-O-β-D-glucuronide, diosmetin-7-O-β-D-glucuronide, tilianin, acacetin-7-O-glucuronide, and acacetin.

The present invention relates to a compound selected from nitazoxanide, tizoxanide, tizoxanide glucuronide and pharmaceutically acceptable salts thereof, for use in a method for the treatment of hepatic impairment.

The invention discloses an application of apigenin-7-O-beta-D-glucuronide in preparation of a medicine for treating fundus diseases, and establishes a model of ischemic fundus diseases of guinea pigs and a model of eyeball conjunctival microcirculation disturbance of rabbits. The prevention and treatment effects of the apigenin-7-O-beta-D-glucuronide on fundus diseases and fundus lesions are researched, and an experimental basis is provided for clinical treatment of the fundus diseases by the apigenin-7-O-beta-D-glucuronide.

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.

The invention relates to a uridine diphosphate-glucuronyl transferase mutant and an application of the uridine diphosphate-glucuronyl transferase mutant in catalytic synthesis of glucuronide. The amino acid sequence of the uridine diphosphate-glucuronyl transferase mutant is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. The invention provides a uridine diphosphate-glucuronyl transferase mutant with high activity and high stability. Compared with wild uridine diphosphate-glucuronyl transferase, the uridine diphosphate-glucuronyl transferase mutant has mutation of 10 amino acid sites. According to experimental determination, the melting temperature of the mutant is increased by 24 DEG C compared with that of a wild type, the activity is increased to 1.65 times, the expression quantity is increased to 4.2 times, and a powerful tool is provided for enzymatic synthesis of glucuronide compounds.

The invention provides a novel application of quercetin-3-O-beta-D-glucuronide, belongs to the technical field of medicines, and particularly relates to an application of the quercetin-3-O-beta-D-glucuronide in preparation of anti-aging medicines. According to the invention, quercetin-3-O-beta-D-glucuronide is extracted and separated from lotus leaves, and quercetin-3-O-beta-D-glucuronide can obviously prolong the service life of caenorhabditis elegans and has the effect of delaying senescence, so that quercetin-3-O-beta-D-glucuronide has the potential of delaying senescence, and can be used for preparing a medicine for treating caenorhabditis elegans. The traditional Chinese medicine composition can be applied to preparation of anti-aging medicines and also can be applied to preparation of health-care products for delaying aging.